Contraception

As teenagers become sexually active, are they fully educated on contraception and pregnancy?

A recent study revealed a significant increase in intrauterine device usage among reproductive-aged women in South Carolina following the implementation of the Choose Well initiative.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Mitchell Creinin, MD, sheds lights on the association between combined oral contraceptives and breast cancer risk, offering valuable insights for clinicians and patients alike.

A comprehensive investigation confirmed Ovaprene's non-hormonal design achieves consistent contraceptive efficacy, paving the way for further pivotal trials in pregnancy risk assessment.

After decades of disappointments, a new generation of male contraceptives is under development and expected to enable men to share the contraceptive burden with their female partners.

Unveiling the intricate relationship between combined oral contraceptive use and breast cancer risk, navigating through research insights and clinical implications for informed patient counseling.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Discover how a web-based decision aid significantly enhances the quality of tubal sterilization decision-making, offering crucial insights for marginalized populations, as revealed in a recent study.

A recent study exposed disparities in contraceptive counseling and use among hypertensive individuals, suggesting a need for tailored contraceptive options, particularly within Black communities.

A recent study revealed Medicaid patients encounter significant obstacles to postpartum sterilization, shedding light on crucial health care access issues.

Online orders began this week for the first over the over-the-counter contraceptive, Opill (norgestrel; Perrigo).

A recent study delves into how serum estradiol decline preceding human chorionic gonadotropin administration affects in vitro fertilization outcomes, particularly among patients without oral contraceptive pretreatment, shedding light on the importance of monitoring during controlled ovarian hyperstimulation.

A randomized trial among young Kenya women showed the post-exposure prophylactic was insignificantly more effective in preventing chlamydia, gonorrhea and syphilis—largely due to inadherence.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Discover effective counseling techniques and overcome barriers to empower adolescents in making informed decisions about contraception, fostering trust, confidentiality, and autonomy in reproductive health care.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Uncover the latest findings on contraceptive methods as researchers delve into the safety, efficacy, and compliance rates of parenteral and oral hormonal contraceptives.

New findings have revealed a decline in emergency contraception-related emergency department visits, indicating increased demand.

A recent study revealed the aftermath of the Dobbs decision, with college students expressing anger and fear, facing pressure to switch to effective contraception.

Explore the potential of monoclonal antibodies for contraception and sexually transmitted infection prevention, providing a comprehensive review of their safety, efficacy, and pharmacokinetics.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The Biden-Harris administration, has released comprehensive guidance through Frequently Asked Questions to eliminate barriers to contraception, ensuring access to FDA-approved contraceptives at no cost, following President Biden's 2023 Executive Order.